174
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 1756-1760 | Received 27 Sep 2020, Accepted 20 Jan 2021, Published online: 17 Feb 2021
 

Disclosure statement

ER is an advisor for Daiichi-Sankyo, Astellas, Abbvie, Celgene and Pfizer; PYD is an advisor for Daiichi-Sankyo, Astellas; PP is an advisor for Jazz, Daiichi-Sankyo, Abbvie and Astellas; MOJ has received honoraria for advisory board from Daichii-Sankyo; AP has received grants from Roche, Celgene, Sunesis, Novartis, Jazz, AbbVie, Astellas, Daiichi-Sankyo and is an advisor for Roche, Celgene, Sunesis, Amgen, Novartis, Jazz, AbbVie, Astellas, Daiichi-Sankyo, Sanofi, Pfizer; CR has received research grants from Amgen, Novartis, Celgene, Jazz Pharmaceuticals, Agios, Chugai, Sunesis, Astellas, and MaatPharma and is an advisor for AbbVie, Sunesis, Janssen, Jazz, Novartis, Celgene, Astellas, Daiichi-Sankyo, Macrogenics, and Pfizer; SB is an advisor for Jazz, Daiichi-Sankyo, Sanofi, and Astellas.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.